About Roche

Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.

 About Biogen 

As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

 About Genpharm

Genpharm is a financially sound privately-owned company based in the Dubai Science Park (DSP), U.A.E. A specialty pharmaceutical company providing partners with fast track market access and sustainable commercial solutions into the Middle East and North Africa (MENA) region and Turkey. We are the preferred regional commercial partner for rare genetic diseases, orphan drugs, and specialty therapeutics. We are the first organization to introduce gene therapy in the MENAT Region. We also provide strategic advice on disease areas, product launches, and go to markets strategies. We operate through evidence-based medicine and at the highest ethical standards. Genpharm is driven by a clear purpose. Our employees, associates, and partners take this to heart. It is apparent in our daily work, in every interaction within our communities and with every partnership we forge. We are #BringingCuresToMENATPatients.

 About AstraZeneca

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. At AstraZeneca, every day starts with the challenge of pushing the boundaries of science to deliver life changing medicine. Our inspiration is to improve 200 million patients across the world. AstraZeneca has been dedicated to providing a valuable contribution to patients’ care. Our success depends on a combination of scientific capabilities. We know the best science doesn’t happen through isolation, it happens through collaboration. When we go to work each day, we know that disease is complex and difficult to treat. But we believe that putting science at the center of everything we do is the best way to understand and transform disease to change people’s lives. In AstraZeneca, we aim at establishing the company as a leader in our focused therapy areas. In an effort to achieve our bold ambition, we are very keen to leverage the following main elements:

Improving patients’ lives through innovative medicines.Implementing high quality Health Care Providers (HCPs) educational initiatives and rollingout valuable Key External Experts (KEEs) engagement projects.Efficient collaboration with local societies to fight disease burden for better outcomes.Building internal capabilities.Ensure fair and motivational environment is dominating our culture.Boosting compliance as the solid background for the entire work process.